Roche group Genentech's 'breakthrough' leukaemia drug obinutuzumab is to undergo an accelerated review by the US Food and Drug Administration following impressive late-stage clinical data.
The Phase III CLL11 trial showed that patients taking obinutuzumab plus the chemotherapy demonstrated a statistically significant 86% reduction in the risk of disease worsening or death. Also, according to the trial, the length of time during which people lived without their disease worsening was more than doubled (23 months versus 10.9 months) when compared…
This content is for subscribers only. Subscribe now for free to read the full article.
Already a subscriber? Login
